Dx Dialogues: Multiple Myeloma

Listen as Associate Professors Dr. Richter, MD, FACP, and Dr. Sborov, MD, MS, both hematologists and medical oncologists, provide expert perspectives on advancing multiple myeloma therapy. Explore key considerations for identifying appropriate patients for combination regimens incorporating CAR-T cell therapy, navigating treatment strategies for refractory disease, and optimizing long-term outcomes following anti-CD38 therapy. They also highlight the importance of thoughtful sequencing approaches that preserve T-cell fitness to support the durability and effectiveness of cellular and other T-cell–redirecting therapies, while examining emerging strategies to overcome resistance as the treatment landscape continues to evolve.